82/100 · Critical
Manufactured by Advagen Pharma Ltd
Topiramate Spinkle Adverse Events: High Seriousness and Diverse Reactions
124,712 FDA adverse event reports analyzed
Last updated: 2026-05-12
TOPIRAMATE SPINKLE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advagen Pharma Ltd. Based on analysis of 124,712 FDA adverse event reports, TOPIRAMATE SPINKLE has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for TOPIRAMATE SPINKLE include DRUG INEFFECTIVE, OFF LABEL USE, HEADACHE, NAUSEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for TOPIRAMATE SPINKLE.
Topiramate Spinkle has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 124,712 adverse event reports for this medication, which is primarily manufactured by Advagen Pharma Ltd.
The most commonly reported adverse events include Drug Ineffective, Off Label Use, Headache. Of classified reports, 76.6% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. High percentage of serious adverse events (76.6%)
Diverse range of reactions including neurological, gastrointestinal, and psychiatric issues Significant number of reports related to weight changes and seizures
Patients taking Topiramate Spinkle should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Topiramate Spinkle has warnings for drug interactions and should be used with caution in combination with other medications. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Topiramate Spinkle received a safety concern score of 82/100 (high concern). This is based on a 76.6% serious event ratio across 47,524 classified reports. The score accounts for 124,712 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 30,606, Male: 10,526, Unknown: 221. The most frequently reported age groups are age 40 (1,347 reports), age 43 (1,091 reports), age 53 (766 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 47,524 classified reports for TOPIRAMATE SPINKLE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Topiramate Spinkle has warnings for drug interactions and should be used with caution in combination with other medications.
If you are taking Topiramate Spinkle, here are important things to know. The most commonly reported side effects include drug ineffective, off label use, headache, nausea, fatigue. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Consult healthcare providers before starting or stopping Topiramate Spinkle to avoid potential interactions with other medications. Monitor for signs of serious adverse events and report them immediately to healthcare providers. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Regulatory oversight is ongoing, with the FDA monitoring safety data and issuing updates as necessary.
The FDA has received approximately 124,712 adverse event reports associated with Topiramate Spinkle. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Topiramate Spinkle include Drug Ineffective, Off Label Use, Headache, Nausea, Fatigue. By volume, the top reported reactions are: Drug Ineffective (6,539 reports), Off Label Use (5,173 reports), Headache (3,436 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Topiramate Spinkle.
Out of 47,524 classified reports, 36,414 (76.6%) were classified as serious and 11,110 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Topiramate Spinkle break down by patient sex as follows: Female: 30,606, Male: 10,526, Unknown: 221. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Topiramate Spinkle adverse events are: age 40: 1,347 reports, age 43: 1,091 reports, age 53: 766 reports, age 41: 687 reports, age 45: 678 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Topiramate Spinkle adverse event reports is Advagen Pharma Ltd. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Topiramate Spinkle include: Pain, Product Use In Unapproved Indication, Migraine, Dizziness, Seizure. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Topiramate Spinkle to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Topiramate Spinkle has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. High percentage of serious adverse events (76.6%)
Key safety signals identified in Topiramate Spinkle's adverse event data include: Severe reactions such as completed suicide and death. High incidence of neurological issues like seizures and confusion. Multiple reports of psychiatric symptoms including depression and anxiety. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Topiramate Spinkle has warnings for drug interactions and should be used with caution in combination with other medications. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Topiramate Spinkle.
Consult healthcare providers before starting or stopping Topiramate Spinkle to avoid potential interactions with other medications. Monitor for signs of serious adverse events and report them immediately to healthcare providers.
Topiramate Spinkle has 124,712 adverse event reports on file with the FDA. Diverse range of reactions including neurological, gastrointestinal, and psychiatric issues The volume of reports for Topiramate Spinkle reflects both the drug's usage level and the vigilance of the reporting community.
Regulatory oversight is ongoing, with the FDA monitoring safety data and issuing updates as necessary. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Advagen Pharma Ltd and compare their safety profiles:
The following drugs share commonly reported adverse reactions with TOPIRAMATE SPINKLE:
Drugs related to TOPIRAMATE SPINKLE based on therapeutic use, drug class, or shared indications: